| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011.
|
Emerg Infect Dis
|
2012
|
1.73
|
|
2
|
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
|
Antiviral Res
|
2009
|
1.66
|
|
3
|
A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
|
Proc Natl Acad Sci U S A
|
2008
|
1.39
|
|
4
|
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
|
Antimicrob Agents Chemother
|
2013
|
1.39
|
|
5
|
Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
|
Emerg Infect Dis
|
2011
|
1.38
|
|
6
|
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
|
Antivir Ther
|
2010
|
1.26
|
|
7
|
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
|
Emerg Infect Dis
|
2013
|
1.25
|
|
8
|
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
|
Viruses
|
2010
|
1.16
|
|
9
|
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
|
Influenza Other Respir Viruses
|
2013
|
1.13
|
|
10
|
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.
|
Influenza Other Respir Viruses
|
2013
|
0.92
|
|
11
|
Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.
|
Bioorg Med Chem Lett
|
2008
|
0.92
|
|
12
|
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.
|
J Med Chem
|
2009
|
0.92
|
|
13
|
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
|
Antiviral Res
|
2012
|
0.86
|
|
14
|
A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.
|
J Infect Dis
|
2012
|
0.85
|
|
15
|
Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.
|
Emerg Infect Dis
|
2013
|
0.81
|
|
16
|
Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016.
|
MMWR Morb Mortal Wkly Rep
|
2016
|
0.79
|
|
17
|
Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs.
|
J Clin Microbiol
|
2011
|
0.79
|
|
18
|
Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.
|
Antimicrob Agents Chemother
|
2013
|
0.76
|
|
19
|
Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.
|
Antimicrob Agents Chemother
|
2011
|
0.76
|
|
20
|
Early Diagnosis of HIV Infection in Infants - One Caribbean and Six Sub-Saharan African Countries, 2011-2015.
|
MMWR Morb Mortal Wkly Rep
|
2016
|
0.75
|